Preparation and application of albumin-bound fusion protein
By fusing the albumin-binding fusion protein with the trimerization domain ABD and the trimerization domain, the specificity of albumin purification and chemotherapy drug vectors was solved, and efficient albumin purification and chemotherapy drugs were achieved. The targeted nature of the tumor is enriched in the tumor, improving the anti-tumor efficacy.
Patent Information
- Application Number
- CN202411123286.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-08-18
- Filing Date
- 2024-08-15
- Publication Date
- 2024-11-26
AI Technical Summary
The existing albumin purification technology is complex and insufficient in specificity. Exogenous albumin is prone to degeneration and loss of activity in chemotherapy drug carriers. When endogenous albumin is used as a drug carrier, chemotherapy drugs can easily dissociate after binding to albumin. , resulting in limited efficacy.
By fusing or expressing the albumin binding domain ABD with the trimerization domain, a high-affinity albumin-binding fusion protein is formed, used for the isolation and purification of albumin and the coupling of chemotherapy drugs, using endogenous albumin as Drug carrier to improve the efficacy of chemotherapy drugs.
The efficient purification of albumin and the efficient targeted enrichment of chemotherapy drugs in the tumor body are achieved, which improves the anti-tumor efficacy and provides higher purification efficiency and efficacy.
Smart Images

Figure CN119019568A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biotechnology drugs, and in particular to the preparation and application of an albumin-binding fusion protein. Background Art
[0002] Albumin is the protein with the highest content in human plasma. It has many physiological functions, such as maintaining body nutrition and plasma osmotic pressure, increasing blood volume, participating in the transport of substances in the body, and anti-inflammatory and antioxidant functions. Human albumin products are widely used in clinical practice. The main indications include hypoalbuminemia, shock caused by blood loss trauma, burns, etc., increased intracranial pressure caused by cerebral edema, edema and ascites caused by cirrhosis, kidney disease, etc., neonatal hyperbilirubinemia and other diseases. Therefore, they are also called life products. Albumin from some animal sources is also widely used in scientific research. At present, albumin is directly separated and purified from plasma using low-temperature ethanol or ammonium sulfate precipitation. These methods have many steps, complex processes, high equipment requirements, and lack of specificity. There is an urgent need to develop new albumin purification technologies.
[0003] In addition to being used directly for disease treatment, albumin is also widely used as a drug carrier due to its long half-life and tumor / inflammatory site targeting, including the use of exogenous albumin and endogenous albumin. The preparation of albumin-bound paclitaxel (Abraxane) is a typical example of using exogenous albumin as a drug carrier. Researchers used nanotechnology to encapsulate paclitaxel into albumin, and the prepared albumin-bound paclitaxel (Abraxane) has been approved for the treatment of various cancers. However, during the cumbersome processing process, exogenous albumin is easily denatured and loses its activity. It may be a better choice to couple the albumin-binding molecules of chemotherapy drugs so that they can quickly bind to endogenous albumin after entering the blood, and use endogenous albumin as a drug carrier.
[0004] The acquisition of high-specificity and high-affinity albumin-binding molecules is the key to whether endogenous albumin can be used as a drug carrier. Existing albumin-binding molecules mainly include fatty acids (FAs), albumin-binding peptides (ABPs) and albumin binding domains (ABDs). FAs have relatively weak affinity for albumin, and there are many binding sites, and the binding products have the problem of low uniformity. ABP and ABD can bind to albumin at a fixed point, and are ideal mediating molecules for using endogenous albumin as a drug carrier. Among them, the most eye-catching is the use of ABD. A series of studies have significantly improved the efficacy of chemotherapy drugs / proteins by coupling ABD monomers with chemotherapeutic drugs or fusing them with proteins. However, it was found in the preliminary work of the present invention that the affinity of monomer ABD for albumin is still not high enough, and it is easy to dissociate after carrying chemotherapeutic drugs and binding to albumin in the blood. In addition, researchers often introduce a certain number of cysteine to achieve site-specific coupling of chemotherapeutic drugs through sulfhydration reaction. Therefore, the number of chemotherapy drugs that a monomer molecule can carry is limited, and the degree of improvement in drug efficacy is limited.
[0005] To overcome the above problems, the present invention prepares high-affinity albumin-binding fusion proteins by fusing trimerization domains to ABD and expressing them in series as trivalent fusion proteins, which are used for separation and purification of albumin and coupling with chemotherapeutic drugs, thereby efficiently utilizing endogenous albumin as a drug carrier and improving the efficacy of chemotherapeutic drugs. Summary of the invention
[0006] To achieve the above object, the present invention provides an albumin-binding fusion protein, which comprises an albumin-binding domain ABD or a domain having a sequence with at least 95% homology to the functional fragment;
[0007] The amino acid sequence of the albumin binding domain is shown in SEQ ID NO.2.
[0008] Furthermore, it also includes a trimerization domain Tri or a domain having a sequence with at least 95% homology to the functional fragment; the amino acid sequence of the trimerization domain is shown in SEQ ID NO.6.
[0009] Furthermore, it is a fusion protein formed by the albumin binding domain ABD fused to the trimerization domain Tri via a (G4S)3 linker;
[0010] The amino acid sequence of the (G4S)3 linker is shown in SEQ ID NO.4.
[0011] Furthermore, a cysteine is added to the end of the trimerization domain Tri of the fusion protein.
[0012] Furthermore, the amino acid sequence of the fusion protein is shown in SEQ ID NO.8.
[0013] Furthermore, it is a fusion protein formed by connecting multiple albumin binding domains ABD in series through a (G4S)3 linker; the amino acid sequence of the linker is shown in SEQ ID NO.4.
[0014] Furthermore, a cysteine is added to the end of the albumin binding domain ABD of the fusion protein.
[0015] Furthermore, the amino acid sequence of the fusion protein is shown in SEQ ID NO.10 or SEQ ID NO.12.
[0016] The present invention also provides a gene fragment, which encodes the above-mentioned fusion protein.
[0017] Furthermore, its nucleotide sequence is shown as SEQ ID NO.7 or SEQ ID NO.9 or SEQ ID NO.11.
[0018] The present invention also provides a recombinant vector, which is a plasmid containing the above gene fragment.
[0019] The present invention also provides a recombinant cell, which is any one of Escherichia coli, yeast, insect, plant or mammalian cells comprising the aforementioned recombinant vector, preferably an Escherichia coli cell.
[0020] The present invention also provides a use of the above fusion protein as an affinity ligand in purifying albumin.
[0021] The present invention also provides a method for purifying albumin, which comprises the following steps:
[0022] Take the sample to be purified, load it onto the chromatography column coupled with the aforementioned fusion protein, elute it with the eluent and collect it.
[0023] Furthermore, the elution solution includes PBS and glycine-hydrochloric acid; the PBS is used to elute unbound proteins, and the glycine-hydrochloric acid is used to elute albumin.
[0024] The present invention also provides a use of the above fusion protein as a drug carrier in the preparation of anti-tumor drugs.
[0025] The present invention also provides an anti-tumor drug, which is a preparation with a chemotherapy drug as an active ingredient coupled with the above-mentioned fusion protein.
[0026] Furthermore, the molar ratio of the chemotherapy drug to the aforementioned fusion protein is 2 to 5:1, preferably 3:1.
[0027] The present invention finally provides a method for preparing the aforementioned anti-tumor drug, which comprises the following steps:
[0028] Take the gel coupled with the above fusion protein, add the chemotherapy drug, mix, and react to obtain the product.
[0029] Furthermore, the molar ratio of the chemotherapy drug to the aforementioned fusion protein is 2 to 5:1, preferably 3:1.
[0030] Furthermore, the reaction temperature is 2-8°C and the reaction time is 2-10 hours, preferably 4°C and the reaction time is 4-5 hours.
[0031] Furthermore, the chemotherapy drugs include VcMMAE and CL2-SN38; and the gel includes Ni-NTA agarose gel.
[0032] The albumin-binding fusion protein obtained by fusing the albumin-binding domain ABD with the trimerization domain or directly expressing them in series can be used for albumin separation and purification, has high specificity and broad spectrum, high purification efficiency, and high albumin purity. In addition, the albumin-binding fusion protein obtained by fusing with the trimerization domain of the present invention has been proven by experiments to be conjugated with chemical drugs, using endogenous albumin as a drug carrier, and targetedly enriched in the tumor body, thereby improving the anti-tumor efficacy, and has broad application prospects in anti-tumor.
[0033] Obviously, according to the above contents of the present invention, in accordance with common technical knowledge and customary means in the art, without departing from the above basic technical ideas of the present invention, other various forms of modification, replacement or change may be made.
[0034] The above contents of the present invention are further described in detail below through specific implementation methods in the form of embodiments. However, this should not be understood as the scope of the above subject matter of the present invention being limited to the following examples. All technologies realized based on the above contents of the present invention belong to the scope of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS
[0035] Figure 1 Preparation of ABD-Tri and ABD;
[0036] Figure 2 Binding of ABD-Tri to human and mouse albumin;
[0037] Figure 3Purification of albumin from different species using ABD-Tri (A: molecular sieve results of purification of albumin from different species using ABD-Tri; B: gel electrophoresis results of albumin purified using ABD-Tri);
[0038] Figure 4 Preparation and cytotoxicity test of ABD-Tri-MMAE (A: gel electrophoresis results after ABD-Tri-MMAE preparation; B: killing of different tumor cells by ABD-Tri-MMAE);
[0039] Figure 5 Binding of ABD-Tri-MMAE to albumin (A: binding of ABD-Tri-MMAE to human albumin; B: binding of ABD-Tri-MMAE to mouse albumin);
[0040] Figure 6 Tissue distribution and anti-tumor effect of ABD-Tri-MMAE (A: Tissue distribution of ABD-Tri-MMAE in colorectal cancer tumor-bearing mouse model; B: Anti-tumor effect of ABD-Tri-MMAE in colorectal cancer tumor-bearing mouse model - tumor volume change C: Anti-tumor effect of ABD-Tri-MMAE in colorectal cancer tumor-bearing mouse model - tumor weight comparison);
[0041] Figure 7 Preparation of ABD-Tri-SN38 and test of its cell killing activity (A: gel electrophoresis results after ABD-Tri-SN38 preparation; B: killing of different tumor cells by ABD-Tri-SN38);
[0042] Figure 8 Recombinant expression, isolation and purification of ABD2 and ABD3;
[0043] Fig. 9 ABD2 and ABD3 were used to purify albumin from different species (A: the effect of ABD2 and ABD3 on human albumin purification; B: the effect of ABD2 and ABD3 on mouse albumin purification). DETAILED DESCRIPTION
[0044] The raw materials and equipment used in the specific embodiments of the present invention are all known products and are obtained by purchasing commercially available products.
[0045] The sequence information involved in the present invention is as follows:
[0046] SEQ ID NO.1: ABD nucleotide sequence
[0047] 5-ctggctgaagcaaaagtcctggcgaatcgtgaactggataagtatggcgtctcggattactacaagaatctgatca ataatgcaaaaaccgtggaaggcgttaaggcactgattgatgaaattctggccgcactgccg-3
[0048] SEQ ID NO.2: ABD amino acid sequence
[0049] NH2-LAEAKVLANRELDKYGVSDYYKNLINNAKTVEGVKALIDEILAA LP-COOH
[0050] SEQ ID NO.3: (G4S) 3 nucleotide sequence
[0051] 5-ggtggtggtggtagcggtggtggtggtagcggtggtggtggtagc-3
[0052] SEQ ID NO.4: (G4S) 3 amino acid sequence
[0053] NH2-GGGGSGGGGSGGGGS-COOH
[0054] SEQ ID NO.5: Tri nucleotide sequence
[0055] 5-ggtagccgtaatctggttaccgcatttagcaatatggatgatatgctgcagaaagcacatctggttattgaaggtacctttatttatctgcgtgatagcaccgaattttttattcgtgttcgtgatggttggaaaaaactgcagctgggtgaactgattccgattccggca-3
[0056] SEQ ID NO.6: Tri amino acid sequence
[0057] NH2-GSRNLVTAFSNMDDMLQKAHLVIEGTFIYLRDSTEFFIRVRDGWKKLQLGELIPIPA-COOH
[0058] SEQ ID NO.7: ABD-Tri nucleotide sequence
[0059] 5-ctggctgaagcaaaagtcctggcgaatcgtgaactggataagtatggcgtctcggattactacaagaatctgatcaataatgcaaaaaccgtggaaggcgttaaggcactgattgatgaaattctggccgcactgccgggtggtggtggtagcggtggtggtggtagcggtggtggtggtagcggtagccgtaatctggttaccgcatttagcaatatggatgatatgctgcagaaagcacatctggttattgaaggtacctttatttatctgcgtgatagcaccgaattttttattcgtgttcgtgatggttggaaaaaactgcagctgggtgaactgattccgattccggcatgc-3
[0060] SEQ ID NO.8: Amino acid sequence of ABD-Tri
[0061] NH2-LAEAKVLANRELDKYGVSDYYKNLINNAKTVEGVKALIDEILAALPGGGGSGGGGSGGGGSGSRNLVTAFSNMDDMLQKAHLVIEGTFIYLRDSTEFFIRVRDGWKKLQLGELIPIPAC-COOH
[0062] SEQ ID NO.9: Nucleotide sequence of ABD2
[0063] 5-ctggctgaagcaaaagtcctggcgaatcgtgaactggataagtatggcgtctcggattactacaagaatctgatcaataatgcaaaaaccgtggaaggcgttaaggcactgattgatgaaattctggccgcactgccgggtggtggtggtagcggtggtggtggtagcggtggtggtggtagcctggctgaagcaaaagtcctggcgaatcgtgaactggataagtatggcgtctcggattactacaagaatctgatcaataatgcaaaaaccgtggaaggcgttaaggcactgattgatgaaattctggccgcactgccgtgc-3
[0064] SEQ ID NO.10: Amino acid sequence of ABD2
[0065] NH2-LAEAKVLANRELDKYGVSDYYKNLINNAKTVEGVKALIDEILAALPGGGGSGGGGSGGGGSLAEAKVLANRELDKYGVSDYYKNLINNAKTVEGVKALIDEILAALPC-COOH
[0066] SEQ ID NO.11: Nucleotide sequence of ABD3
[0067] 5-ctggctgaagcaaaagtcctggcgaatcgtgaactggataagtatggcgtctcggattactacaagaatctgatcaataatgcaaaaaccgtggaaggcgttaaggcactgattgatgaaattctggccgcactgccgggtggtggtggtagcggtggtggtggtagcggtggtggtggtagcctggctgaagcaaaagtcctggcgaatcgtgaactggataagtatggcgtctcggattactacaagaatctgatcaataatgcaaaaaccgtggaaggcgttaaggcactgattgatgaaattctggccgcactgccgggtggtggtggtagcggtggtggtggtagcggtggtggtggtagcctggctgaagcaaaagtcctggcgaatcgtgaactggataagtatggcgtctcggattactacaagaatctgatcaataatgcaaaaaccgtggaaggcgttaaggcactgattgatgaaattctggccgcactgccgtgc-3
[0068] SEQ ID NO.12: Amino acid sequence of ABD3
[0069] NH2-LAEAKVLANRELDKYGVSDYYKNLINNAKTVEGVKALIDEILAALPGGGGSGGGGSGGGGSLAEAKVLANRELDKYGVSDYYKNLINNAKTVEGVKALIDEILAALPGGGGSGGGGSGGGGSLAEAKVLANRELDKYGVSDYYKNLINNAKTVEGVKALIDEILAALPC-COOH
[0070] Example 1 Preparation of albumin-binding fusion protein ABD-Tri
[0071] In order to improve the binding ability of ABD to albumin, the present invention designs to connect ABD (SEQ ID NO.1) to the trimerization domain Tri (SEQ ID NO.5) through (G4S)3 (SEQ ID NO.3). In order to couple chemical drugs through sulfhydryl reaction, a cysteine is added to the end of ABD-Tri to obtain ABD-Tri (SEQ ID NO.7). The coding gene of ABD-Tri is artificially synthesized and cloned into pQE30 according to conventional molecular biological methods and then transferred into E. coli M15. To induce ABD-Tri expression, 1mM isopropylβ-D-thiogalactoside (IPTG) was added to the bacteria, cultured overnight at 26°C, and the cells were collected and re-selected in lysis buffer (50mM phosphate, pH 8.0, 300mM sodium chloride, 20mM imidazole, and 10mMβ-mercaptoethanol), and high-pressure homogenized. The target protein in the supernatant was separated and purified by conventional Ni-NTA affinity chromatography. The results are shown in Figure 1 As shown in FIG. 1 , the purified protein was shown as a single component on the polyacrylamide electrophoresis gel, indicating that the present invention obtained pure ABD-Tri. The separated and purified ABD-Tri was dialyzed against phosphate buffer (PBS, 10 mM Na2HPO4, 137 mM NaCl, 2.68 mM KCl, 2 mM KH2PO4, pH 7.4) overnight for later use. The same method was used to obtain pure ABD ( Figure 1 ).
[0072] Example 2 Binding of ABD-Tri to Albumin
[0073] The binding of ABD-Tri to albumin was determined using conventional ELISA methods. First, 200 μL of albumin (10 mg / ml) dissolved in PBS was added to a 96-well plate for ELISA and coated overnight at 4°C. Wash three times with phosphate buffered saline (PBST) containing 500 mM NaCl and 0.05% Tween 20 to remove excess albumin, and then add different concentrations of biotin-labeled ABD-Tri to the wells and continue incubating at room temperature for 1 hour. After washing three times with PBST, horseradish peroxidase-labeled streptavidin (horseradish peroxidase (HRP)-streptavidin) was added for color development and the absorbance was measured at 450 nm. ABD was used as a control. Figure 2 As shown, human serum albumin (HSA) was coated into a well plate, and then different concentrations of ABD-Tri or ABD were added. It was found that the amount of ABD-Tri bound to the well plate increased with the increase in the amount added, indicating that ABD-Tri can bind to HSA. However, under the same conditions, the amount of ABD bound to the well plate did not increase significantly with the increase in the amount added, indicating that ABD-Tri has a stronger binding ability to HSA than ABD. Testing with mouse serum albumin (MSA) also found the same rule, and ABD-Tri had a significantly stronger binding ability to MSA than ABD. These results show that after the albumin binding domain ABD is fused with the trimerization domain Tri in the present invention, the binding ability of ABD to albumin is significantly enhanced.
[0074] Example 3 Application of ABD-Tri in albumin purification
[0075] In order to test whether ABD-Tri can be used as an affinity ligand for albumin purification, ABD-Tri was coupled to a 1 mL HiTrap NHS-activated HP prepacked column (GE) according to the instructions to prepare an ABD-Tri-HP affinity chromatography column. The ABD-Tri-HP column was equilibrated with PBS, and then the plasma from different species was diluted 4 times with PBS, and 600 μL was loaded onto the column for purification. The purification process was completed on HPLC using PBS as the mobile phase. After the unbound proteins were washed clean, they were eluted with glycine-hydrochloric acid at pH 2.5. The protein purity and molecular weight were checked by polyacrylamide gel electrophoresis and compared with commercial albumin products. The results are shown in Figure 2. Figure 3 As shown in A, a large amount of protein can be eluted from human plasma after passing through the ABD-Tri-HP affinity column. Further electrophoresis showed that the eluted proteins were all single components, which were consistent with the purity and molecular weight of commercial HSA (HSA(c)) ( Figure 3B). It shows that HSA can be separated and purified from human plasma by affinity chromatography using ABD-Tri as a ligand. Similarly, rhesus monkey albumin (RhSA), mouse albumin (MSA) and rat albumin (RSA) can be purified from rhesus monkey, mouse and rat plasma using ABD-Tri-HP affinity columns.
[0076] Example 4 ABD-Tri mediates the binding of chemotherapeutic drugs to albumin
[0077] The chemotherapy drugs were coupled to ABD-Tri using the solid phase coupling method. First, referring to the conventional Ni-NTA affinity chromatography method, the ABD-Tri protein (1-1.5 mg / mL) was incubated with the Ni-NTA agarose gel at 4°C overnight to allow ABD-Tri to bind to the gel. The gel was washed with PBS to remove the unbound ABD-Tri. Then, the chemical drugs dissolved in PBS, such as VcMMAE, CL2-SN38, etc., were added to the gel bound to ABD-Tri at a molar ratio of 3:1 to ABD-Tri, and reacted at 4°C for 4-5 hours to allow the chemotherapy drugs to couple to ABD-Tri. The gel was then washed thoroughly with PBS to remove the uncoupled chemotherapy drugs. Finally, the conjugate of ABD-Tri and the chemical drug was eluted with PBS containing 300 mM imidazole, and dialyzed against PBS overnight for later use. The results are as follows. Figure 4 As shown in A, the molecular weight of the conjugate of VcMMAE and ABD-Tri, ABD-Tri-MMAE, is larger than that of ABD-Tri, indicating that VcMMAE and ABD-Tri are successfully conjugated. In order to determine whether the chemotherapeutic drugs retain their cell killing activity after conjugation with ABD-Tri, the cell killing of ABD-Tri-MMAE and VcMMAE was compared. A certain number of cells (1-2×10 4 ) were inoculated into a 96-well plate for cell culture, and then different concentrations of drugs were added for 72 hours. The number of surviving cells was determined by CCK-8 method. The survival rate of cells treated with PBS was 100%, and the killing rate of the drug on the cells was calculated. The killing rate of different concentrations of drugs was used to draw a curve, and the half-maximal growth inhibitory dose IC50 of the drug was calculated. The results are shown in Figure 4 As shown in B, similar to VcMMAE, ABD-Tri-MMAE showed killing effects on all tested tumor cells, indicating that coupling with ABD-Tri did not lead to a significant decrease in its activity.
[0078] Whether endogenous albumin can be used as a drug carrier depends on the binding ability of ABD-Tri-MMAE to albumin. Therefore, the binding of ABD-Tri-MMAE to HSA and MSA was analyzed by gel filtration chromatography. ABD-Tri-MMAE and HSA were first mixed and combined at room temperature for 30 minutes, and then gel filtration chromatography was used to analyze whether a complex with a larger molecular weight was formed. The results are shown in Figure 2. Figure 5 As shown in A, the molecular weight of the mixture of ABD-Tri-MMAE and HSA is significantly greater than the molecular weight of each of them, indicating that ABD-Tri-MMAE and HSA form a complex. Under the same conditions, it was found that ABD-Tri-MMAE and MSA also formed a complex ( Figure 5 B) These results indicate that ABD-Tri-MMAE can bind to albumin.
[0079] Further tissue distribution analysis revealed that the amount of ABD-Tri-MMAE in the heart, liver, spleen, lung, and kidney was less than that of VcMMAE, but its content in tumors was higher than that of VcMMAE, suggesting that ABD-Tri-MMAE can tightly bind to albumin and utilize the targeting property of albumin to be enriched in the tumor ( Figure 6 A). Using the COLO205 subcutaneous tumor model, it was found that when the average volume of the subcutaneous tumor reached 50 mm 3 At 14:1, ABD-Tri-MMAE or vcMMAE was injected into the tail vein at a dose of 0.3 mg / kg MMAE. The drug was administered again every two days, and tumor growth was observed regularly and tumor volume was measured. At the end of the observation, the mice were killed, and the tumors were weighed and photographed. Figure 6 As shown in B, the tumor growth of the ABD-Tri-MMAE and vcMMAE treatment groups was significantly slower than that of the PBS treatment group, indicating that both have anti-tumor activity. However, the tumor growth of the ABD-Tri-MMAE treatment group was slower, indicating that the anti-tumor activity of ABD-Tri-MMAE was stronger than that of vcMMAE. At the end of the observation, the tumors were removed and weighed. It was found that among the 6 mice treated with ABD-Tri-MMAE, the tumors of 2 mice completely regressed, and the tumor weight was significantly lighter than that of the vcMMAE treatment group, further proving that the anti-tumor effect of ABD-Tri-MMAE is better than that of vcMMAE, indicating that after the chemotherapeutic drug is coupled to ABD-Tri, when it enters the blood, it can use endogenous albumin as a carrier, enrich more in the tumor site, and show stronger anti-tumor activity. (*p<0.05, **p<0.01, ***p<0.001).
[0080] In addition to coupling vcMMAE, we also coupled the chemotherapy drug CL2-SN38 to ABD-Tri using the same solid phase coupling method. Figure 7As shown in A, the coupling product of CL2-SN38 and ABD-Tri, ABD-Tri-SN38, showed a molecular weight greater than ABD-Tri on the polyacrylamide gel, indicating that CL2-SN38 was successfully coupled with ABD-Tri by solid phase coupling. Cell killing activity analysis found that ABD-Tri-SN38 was similar to CL2-SN38 and showed cytotoxicity to the tested tumor cells ( Figure 7 B), indicating that CL2-SN38 still maintained its original cytotoxicity and anti-tumor activity after being coupled with ABD-Tri.
[0081] Example 5 Preparation of albumin-binding fusion proteins ABD2 and ABD3
[0082] In order to improve the binding ability of ABD to albumin, in addition to fusing ABD with Tri, the present invention also attempts to connect two or three ABDs in series through (G4S)3 to prepare a new fusion protein ABD2 or ABD3. In order to couple chemotherapeutic drugs through sulfhydryl reaction, a cysteine is added to the end of the molecule. To obtain the fusion protein, the ABD gene is first connected in series according to the molecular design to obtain a gene fragment encoding the fusion protein (shown in SEQ ID NO.9 or SEQ ID NO.11), and then the company is commissioned to synthesize and clone it into pQE30 for expression. The results are shown in Figure 8 As shown, according to the method of Example 1, ABD2 (SEQ ID NO.10) and ABD3 (SEQ ID NO.12) obtained were shown as a single component on the polyacrylamide electrophoresis gel, indicating that pure ABD2 and ABD3 were obtained.
[0083] Example 6 Application of ABD2 and ABD3 in albumin purification
[0084] In order to test whether ABD2 and ABD3 can be used as affinity ligands for albumin purification, ABD, ABD2 and ABD3 were coupled to NHS-activated Sepharose according to the instructions. TM ABD-Sepharose, ABD2-Sepharose and ABD3-Sepharose affinity beads were prepared in 4Fast Flow (GE). 100 μL of coupled affinity beads were added to 450 μL of human and mouse plasma diluted 15 times with PBS, and the beads were rotated and bound at room temperature for 30 minutes. After washing non-specific binding substances with PBS, they were eluted with glycine-hydrochloric acid at pH 2.5. The protein purity and molecular weight were determined by polyacrylamide gel electrophoresis, and the protein concentration was determined by Bradford method. The results are shown in Figure 2. Fig. 9As shown in A, human plasma can elute a large amount of protein after passing through three types of affinity beads. Among them, 4.018±0.127 mg of albumin can be purified per 1 ml of affinity beads in the ABD group, 3.755±0.255 mg in the ABD2 group, and 3.797±1.037 mg in the ABD3 group. For mouse plasma ( Fig. 9 B), 5.908±0.612 mg of albumin can be purified per 1 ml of affinity beads in the ABD group, 6.013±0.215 mg in the ABD2 group, and 5.896±0.361 mg in the ABD3 group. These results indicate that ABD, ABD2, and ABD3 can be used as ligands to separate and purify the corresponding albumin from human or mouse plasma by affinity chromatography.
[0085] In summary, the albumin-binding fusion protein obtained by fusing the albumin-binding domain ABD with the trimerization domain or directly expressing them in series can be used for albumin separation and purification, has high specificity and broad spectrum, high purification efficiency, and the obtained albumin has high purity. In addition, the albumin-binding fusion protein formed by fusion with the trimerization domain of the present invention has been proven by experiments to be conjugated with chemical drugs, using endogenous albumin as a drug carrier, and targeted enrichment in the tumor body, thereby improving the anti-tumor efficacy, and has broad application prospects in anti-tumor.
Claims
1. An albumin-binding fusion protein, characterized in that: It comprises an albumin binding domain ABD or a domain having a sequence with at least 95% homology to the functional fragment, and a trimerization domain Tri or a domain having a sequence with at least 95% homology to the functional fragment; The amino acid sequence of the albumin binding domain is shown in SEQ ID NO.2; The amino acid sequence of the trimerization domain is shown in SEQ ID NO.
6.
2. The fusion protein according to claim 1, characterized in that: It is a fusion protein formed by the albumin binding domain ABD fused to the trimerization domain Tri via a (G4S)3 linker; The amino acid sequence of the (G4S)3 linker is shown in SEQ ID NO.4; A cysteine is added to the end of the trimerization domain Tri of the fusion protein; Preferably, the amino acid sequence of the fusion protein is shown in SEQ ID NO.
8.
3. The fusion protein according to claim 1, characterized in that: It is a fusion protein composed of multiple albumin binding domains ABD connected in series through a (G4S)3 linker; The amino acid sequence of the linker is shown in SEQ ID NO.4; A cysteine is added to the end of the albumin binding domain ABD of the fusion protein; Preferably, the amino acid sequence of the fusion protein is shown as SEQ ID NO.10 or SEQ ID NO.
12.
4. A gene fragment, characterized in that: It encodes the fusion protein according to any one of claims 1 to 3, and its nucleotide sequence is shown as SEQ ID NO.7 or SEQ ID NO.9 or SEQ ID NO.
11.
5. A recombinant vector, characterized in that: The plasmid comprises the gene fragment according to claim 4.
6. A recombinant cell, characterized in that: It is any one of Escherichia coli, yeast, insect, plant or mammalian cells comprising the recombinant vector of claim 5, preferably Escherichia coli cells.
7. Use of the fusion protein according to any one of claims 1 to 3 as an affinity ligand in purifying albumin, characterized in that: The method for purifying albumin comprises the following steps: Take the sample to be purified, load it on the chromatography column coupled with the fusion protein according to any one of claims 1 to 3, elute with the eluent and collect, and obtain; The elution solution includes PBS and glycine-hydrochloric acid; the PBS is used to elute unbound proteins, and the glycine-hydrochloric acid is used to elute albumin.
8. Use of the fusion protein according to any one of claims 1 to 3 as a drug carrier in the preparation of anti-tumor drugs.
9. An anti-tumor drug, characterized in that: It is a preparation with a chemotherapeutic drug as an active ingredient coupled with the fusion protein according to any one of claims 1 to 3; The molar ratio of the chemotherapy drug to the fusion protein according to any one of claims 1 to 3 is 2 to 5:1, preferably 3:
1.
10. A method for preparing the antitumor drug according to claim 9, characterized in that: It includes the following steps: Take the gel coupled with the fusion protein according to any one of claims 1 to 3, add the chemotherapeutic drug, mix and react to obtain; The molar ratio of the chemotherapy drug to the fusion protein according to any one of claims 1 to 3 is 2 to 5:1, preferably 3:1; The reaction temperature is 2-8°C, the time is 2-10 hours, preferably the temperature is 4°C, the time is 4-5 hours; The chemotherapy drugs include VcMMAE and CL2-SN38; and the gel includes Ni-NTA agarose gel.
